Biomarkers for EGFR-antagonist response: In the genes and on the genes!

Research output: Contribution to journalShort surveypeer-review

Abstract

Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.

Original languageEnglish (US)
Pages (from-to)2121-2123
Number of pages3
JournalClinical Cancer Research
Volume18
Issue number8
DOIs
StatePublished - Apr 15 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Biomarkers for EGFR-antagonist response: In the genes and on the genes!'. Together they form a unique fingerprint.

Cite this